Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump

David Dalvey sold 20,000 shares indirectly on Jan. 27, 2026 for a transaction value of ~$2.4 million, at a weighted average price of $120.03 per share. The transaction represented 18.18% of Dalvey's total indirect holdings prior to the sale, reducing his stake from 110,000 to 90,000 shares.

The Motley Fool • Feb 6, 2026

Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026

MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 to be held in New York, New York on February 11-12, 2026.

GlobeNewsWire • Feb 4, 2026

These 20 stocks are strong choices for momentum investors

“Big mo” is an “eternal feature” of financial markets worldwide.

Market Watch • Jan 22, 2026

Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing its New Drug Application (“NDA”) for gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), PIK3CA wild-type advanced breast cancer (“ABC”). The FDA granted Priority Review and assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of July 17, 2026.

GlobeNewsWire • Jan 20, 2026

Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase?

CELC shares surge as NDA filing and strong phase III data boost optimism around gedatolisib's potential.

Zacks Investment Research • Jan 6, 2026

Celcuity: After Stellar 2025, I Predict More Success In 2026 And Beyond

Celcuity Inc. surged over 750% in 2025 on best-in-class Phase 3 data for gedatolisib in HR+/HER2- advanced breast cancer. GEDATOLISIB demonstrated superior efficacy and safety versus standards of care, with median PFS of 9.3 months in VIKTORIA-1 and favorable adverse event profile. Management projects peak revenues of $2.5–$3 billion for gedatolisib; current cash position is nearly $500 million, supporting regulatory and commercial milestones.

Seeking Alpha • Dec 24, 2025

5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026

After a weak first half, the drug and biotech sector has recovered in the past 2-3 months with large drugmakers like Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk signing drug pricing agreements with the Trump administration. A rebound in mergers and acquisitions (M&A) has also increased investor confidence in the industry.

Zacks Investment Research • Dec 16, 2025

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

MINNEAPOLIS, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated results from the randomized, Phase 3 VIKTORIA-1 trial for gedatolisib, a multi-target PI3K/AKT/mTOR (“PAM”) inhibitor, in adults with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-“), PIK3CA wild-type (“WT”), advanced breast cancer (“ABC”), following progression on, or after, treatment with a CDK4/6 inhibitor and an aromatase inhibitor. The additional study results were presented in an oral presentation session at the 2025 San Antonio Breast Cancer Symposium (“SABCS”) today, Thursday, December 11.

GlobeNewsWire • Dec 11, 2025

Tracking the Top-Performing Russell 2000 Stocks Against the Zacks Rank

Surprisingly, the Russell 2000 has a chance to be the second-best-performing index on the U.S. stock exchanges as we start to round out 2025, with the unprecedented push into small caps being inspired by the Fed's easing cycle.

Zacks Investment Research • Dec 12, 2025

3 Stocks You'll Wish You Bought Before 2026

Many investors have profited from the artificial intelligence (AI) trade in 2025. But there have been several up-and-coming stocks in other sectors that have posted impressive gains this year.

MarketBeat • Dec 3, 2025